R&D Costs and Productivity in Biopharmaceuticals
This article characterizes the activities required to launch a new pharmaceutical molecule into the market, summarizes studies that have attempted to pinpoint the research and development costs incurred per approved new molecule, and analyzes the various critiques levied against published R&D cost estimates. It finds that by any reckoning, R&D costs per approved molecule have risen sharply over time, most likely at a rate of approximately 7 percent per year after stripping out the effects of general economic inflation.
|Date of creation:||2011|
|Date of revision:|
|Publication status:||Published in HKS Faculty Research Working Paper Series|
|Contact details of provider:|| Postal: |
Web page: http://www.hks.harvard.edu/
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:hrv:hksfac:5688848. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Ben Steinberg)
If references are entirely missing, you can add them using this form.